Nikhil Akkoo’s Post

The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.

Orchard is counting on the long-term data it’s accrued to convince insurers to cover Lenmeldy’s $4.25 million list price, the highest of any genetic medicine to come to market!

The Boston-based company is debuting with $82 million from a group of investors that include Novartis’ venture arm and the gene editing biotech CRISPR Therapeutics for genetic medicine!

***𝗠𝗔𝗥𝗞𝗘𝗧 𝗔𝗖𝗖𝗘𝗦𝗦 𝗡𝗘𝗧𝗪𝗢𝗥𝗞 - 𝗗𝗜𝗥𝗘𝗖𝗧𝗢𝗥 𝗟𝗘𝗩𝗘𝗟 𝗣𝗢𝗦𝗜𝗧𝗜𝗢𝗡*** I am currently working with an incredibly exciting organization focused on developing and commercializing advanced cell therapies for serious medical conditions. I am on the search for a 𝐃̲𝐢̲𝐫̲𝐞̲𝐜̲𝐭̲𝐨̲𝐫̲ ̲𝐨̲𝐟̲ ̲𝐌̲𝐚̲𝐫̲𝐤̲𝐞̲𝐭̲ ̲𝐀̲𝐜̲𝐜̲𝐞̲𝐬̲𝐬̲ with extensive Burn Care experience. Ideally, someone who understands the challenges of a smaller organization and wants to be part of a growing Market Access division. To learn more, please reach out to me or email me at 𝒏𝒊𝒌𝒉𝒊𝒍.𝒂𝒌𝒌𝒐𝒐@𝒃𝒊𝒐𝒕𝒂𝒍𝒆𝒏𝒕.𝒄𝒐𝒎

𝐈𝐬 𝐭𝐡𝐞 𝐥𝐢𝐟𝐞 𝐬𝐜𝐢𝐞𝐧𝐜𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐮𝐧𝐝𝐞𝐫 𝐭𝐡𝐞 𝐰𝐞𝐚𝐭𝐡𝐞𝐫? While there's always innovation brewing in life sciences, it's no secret the market is facing some headwinds in 2024. Let's be honest: layoffs, restructuring, and a focus on cost-effectiveness can be disheartening. 𝐇𝐞𝐫𝐞'𝐬 𝐚 𝐫𝐞𝐚𝐥𝐢𝐭𝐲 𝐜𝐡𝐞𝐜𝐤: • Consolidation wave: Mergers and acquisitions are creating uncertainty, with some companies trimming their workforce. • Value over everything: Payers are demanding hard data on a therapy's worth, putting pressure on market access strategies. • Job market flux: While some roles are in high demand (think value-based pricing experts!), others are facing a squeeze. 𝐁𝐮𝐭 𝐡𝐞𝐫𝐞'𝐬 𝐭𝐡𝐞 𝐠𝐨𝐨𝐝 𝐧𝐞𝐰𝐬: • Innovation marches on: Gene therapy, cell therapy, and other exciting fields are experiencing significant growth. • Real-world data is king: Companies leveraging real-world data effectively are gaining an edge. • The patient voice matters more than ever: Engaging with patient communities opens doors for better market access. The question is, how do we navigate this changing landscape? 𝐏.𝐒. Even in a tough market, top talent is always in demand. If you're a high performer in the Market Access space looking for your next opportunity, reach out and let's connect! #lifesciences #pharma #biotech #marketchallenges #careeradvice #marketaccess #HEOR #payerrelations #patientaccess #patientsupport #raredisease #oncology #cellandgenetherapy

𝑰𝒔 𝒕𝒉𝒊𝒔 𝒕𝒉𝒆 𝒆𝒏𝒅 𝒐𝒇 𝒕𝒉𝒆 𝑩𝒊𝒐𝒔𝒊𝒎𝒊𝒍𝒂𝒓'𝒔 𝒎𝒂𝒓𝒌𝒆𝒕??? Speaking to Market Access professionals day in, day out - I've noticed a big trend in the market which is, many organizations now trying to move away from the Biosimilars space but why?? The biosimilars market, once projected for explosive growth, seems to be hitting a snag. While biosimilars offer a more affordable alternative to biologic drugs, recent reports suggest a slowdown in some regions. Is the promise of biosimilars fading? 𝐋𝐞𝐭'𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬: • US Market Lag: Despite advantages, biosimilar adoption in the US lags behind Europe. Factors like limited interchangeability designations and pharmacy benefit manager (PBM) practices could be contributing • Shifting Pipeline Focus: Studies suggest a potential decline in the number of biosimilars in development, particularly for oncology drugs. • Orphan Drug Challenge: The economic viability of developing biosimilars for rare diseases (orphan drugs) is often limited due to smaller patient pools. Is this a temporary blip or a sign of deeper issues? Are there policy changes needed to incentivize biosimilar adoption? How can we ensure biosimilars remain a viable option for patients and healthcare systems? Share your thoughts! #biosimilars #pharmaceuticals #healthcarecosts #drugaccess #innovation #generics #marketaccess #patientaccess

𝑹𝒂𝒓𝒆 𝑫𝒊𝒔𝒆𝒂𝒔𝒆𝒔: 𝑨 𝑩𝒐𝒐𝒎𝒊𝒏𝒈 𝑵𝒊𝒄𝒉𝒆 𝒊𝒏 𝑩𝒊𝒐𝒕𝒆𝒄𝒉 & 𝑷𝒉𝒂𝒓𝒎𝒂 The tides are turning for treatments of rare diseases! Biotech and pharma companies are increasingly investing in this area, and here's why: • 𝐎𝐫𝐩𝐡𝐚𝐧 𝐃𝐫𝐮𝐠 𝐀𝐜𝐭 𝐈𝐦𝐩𝐚𝐜𝐭: This legislation provides significant incentives for developing treatments for rare diseases, making them financially viable for companies [Source: National Organization for Rare Disorders]. • 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐏𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧: Millions suffer from rare diseases, and the need for effective treatments is immense. Investors are recognizing this unmet medical need. • 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: Breakthroughs in gene therapy, gene editing, and personalized medicine are opening doors for new therapies specifically targeted at rare diseases. 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐑𝐢𝐬𝐞: We're seeing a surge in funding for rare disease research and development. Dedicated venture capital firms are focusing solely on rare diseases. Success stories of companies developing treatments for previously neglected conditions are attracting more investment. 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐑𝐞𝐦𝐚𝐢𝐧: • High development costs and smaller patient pools require innovative financing models. • Ensuring equitable access to these potentially life-saving treatments is crucial. Join the discussion! #rarediseases #biotech #pharma #drugdiscovery #orphandrugs #patientcare #marketaccesss #patientaccess

**𝐍𝐄𝐖 𝐎𝐏𝐏𝐎𝐑𝐓𝐔𝐍𝐈𝐓𝐘** I am currently partnered with a dynamic and rapidly growing Clinical Stage Oncology Biotech on the search for a Senior Manager of Market Access. If you want to learn more about this opportunity or if you are beginning your job search in Market Access, it would be great to connect for an open conversation! Reach out to me on 𝒏𝒊𝒌𝒉𝒊𝒍.𝒂𝒌𝒌𝒐𝒐@𝒃𝒊𝒐𝒕𝒂𝒍𝒆𝒏𝒕.𝒄𝒐𝒎 Let's chat!